PMID- 29582252
OWN - NLM
STAT- MEDLINE
DCOM- 20190110
LR  - 20191210
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 37
IP  - 8
DP  - 2018 Aug
TI  - Safety and efficacy of alternate-day corticosteroid treatment as adjunctive 
      therapy for rheumatoid arthritis: a comparative study.
PG  - 2027-2034
LID - 10.1007/s10067-018-4073-7 [doi]
AB  - Corticosteroids (CSs), used to treat rheumatoid arthritis (RA), confer a risk of 
      adverse events (AEs). This study investigated the safety and efficacy of 
      alternate-day (QOD) CS therapy for RA. All patients (> 18 years) who started oral 
      CS therapy for RA, between 2005 and 2014, at our hospital were retrospectively 
      analysed. The patients were divided into the daily (QD) and QOD CS therapy groups 
      to investigate the rates of CS-related major AEs (infection, diabetes, 
      hypertension, cardiovascular events and fragility fractures) within the first 
      year of treatment. The number of patients free from CS treatment at 1 year and 
      the mean decreases in C-reactive protein (CRP) levels at 1 month were also 
      investigated. In total, 138 patients were analysed (QD group, 68; QOD group, 70). 
      The maximum daily CS dose was not significantly different between the two groups, 
      but the annual cumulative dose was significantly lower in the QOD group 
      (P < 0.01). The infection rate was significantly lower in the QOD group (24.3%) 
      than in the QD group (50.0%; P < 0.01), whereas the other AE rates were similar 
      between the groups. The CS-free rate at 1 year was significantly higher in the 
      QOD group (58.6%) than in the QD group (26.5%; P < 0.01). The mean CRP decreases 
      over 1 month of CS therapy were not significantly different between the groups. 
      QOD CS treatment leads to a lower infection rate and less CS dependence than does 
      daily treatment; both RA treatments are equally effective.
FAU - Suda, Masei
AU  - Suda M
AUID- ORCID: 0000-0002-2036-6216
AD  - Immuno-Rheumatology Centre, St. Luke's International Hospital, St. Luke's 
      International University, 9-1 Akashi-cho Chuo-ku, Tokyo, 104-8560, Japan. 
      msuda@luke.ac.jp.
FAU - Ohde, Sachiko
AU  - Ohde S
AD  - Graduate School of Public Health, OMURA Susumu and Mieko Memorial St. Luke's 
      Centre for Clinical Academia, St. Luke's International University, 5th Floor, 
      3-6-2 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Tsuda, Tokutaro
AU  - Tsuda T
AD  - Immuno-Rheumatology Centre, St. Luke's International Hospital, St. Luke's 
      International University, 9-1 Akashi-cho Chuo-ku, Tokyo, 104-8560, Japan.
FAU - Kishimoto, Mitsumasa
AU  - Kishimoto M
AD  - Immuno-Rheumatology Centre, St. Luke's International Hospital, St. Luke's 
      International University, 9-1 Akashi-cho Chuo-ku, Tokyo, 104-8560, Japan.
FAU - Okada, Masato
AU  - Okada M
AD  - Immuno-Rheumatology Centre, St. Luke's International Hospital, St. Luke's 
      International University, 9-1 Akashi-cho Chuo-ku, Tokyo, 104-8560, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20180326
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antirheumatic Agents)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Administration, Oral
MH  - Adrenal Cortex Hormones/*administration & dosage/*adverse effects
MH  - Antirheumatic Agents/therapeutic use
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - C-Reactive Protein/analysis
MH  - Chemotherapy, Adjuvant
MH  - Diabetes Mellitus/chemically induced
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Infections/chemically induced
MH  - Japan
MH  - Male
MH  - Methylprednisolone/administration & dosage/adverse effects
MH  - Middle Aged
MH  - Prednisolone/administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse events
OT  - Corticosteroids
OT  - Infection
OT  - Rheumatoid arthritis
EDAT- 2018/03/28 06:00
MHDA- 2019/01/11 06:00
CRDT- 2018/03/28 06:00
PHST- 2018/02/21 00:00 [received]
PHST- 2018/03/15 00:00 [accepted]
PHST- 2018/03/13 00:00 [revised]
PHST- 2018/03/28 06:00 [pubmed]
PHST- 2019/01/11 06:00 [medline]
PHST- 2018/03/28 06:00 [entrez]
AID - 10.1007/s10067-018-4073-7 [pii]
AID - 10.1007/s10067-018-4073-7 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2018 Aug;37(8):2027-2034. doi: 10.1007/s10067-018-4073-7. Epub 
      2018 Mar 26.